Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Lyell Immunopharma, Inc. (LYEL) had Return on Investments of -110.57% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.04M |
|
$-274.45M |
|
-- |
|
$0.04M |
|
$269.44M |
|
$-269.40M |
|
$-5.04M |
|
$-274.45M |
|
$-274.45M |
|
$-274.45M |
|
$-274.45M |
|
$-274.45M |
|
$-274.45M |
|
$-269.40M |
|
$-262.82M |
|
17.09M |
|
17.09M |
|
$-16.06 |
|
$-16.06 |
|
| Balance Sheet Financials | |
$260.94M |
|
$34.77M |
|
$79.11M |
|
$340.05M |
|
$49.41M |
|
-- |
|
$42.44M |
|
$91.85M |
|
$248.20M |
|
$248.20M |
|
$248.20M |
|
21.25M |
|
| Cash Flow Statement Financials | |
$-150.02M |
|
$54.10M |
|
$50.41M |
|
$107.29M |
|
$61.77M |
|
$-45.52M |
|
$41.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-748344.40% |
|
-748344.40% |
|
-730066.70% |
|
-762355.60% |
|
-762355.60% |
|
$-191.71M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-110.57% |
|
-110.57% |
|
-80.71% |
|
|
Return on Investments |
-110.57% |
$11.68 |
|
$-11.22 |
|
$-8.78 |
|